Curated News
By: NewsRamp Editorial Staff
November 02, 2026
Okogen Doses First Patient in EMERALD Trial for Conjunctivitis Treatment
TLDR
- Okogen advances Treyegen into Phase 1/2, potentially capturing the acute infectious conjunctivitis market with a first-in-class triple-action antiviral.
- The EMERALD Trial evaluates Treyegen's safety, tolerability, and antiviral/antibacterial activity in patients with acute infectious conjunctivitis.
- Okogen's Treyegen could offer a single treatment for acute infectious conjunctivitis, improving patient outcomes and reducing uncertainty in diagnosis.
- Treyegen combines antiviral, antibacterial, and symptom-relieving mechanisms, potentially addressing unknown causes of conjunctivitis in one therapy.
Impact - Why it Matters
This news matters because acute infectious conjunctivitis, commonly known as pink eye, affects millions worldwide and often lacks a targeted treatment when the cause is unknown. Treyegen™ could offer a much-needed single therapy that addresses viral and bacterial causes while relieving symptoms, potentially reducing unnecessary antibiotic use and improving patient outcomes. Moreover, the trial’s progress validates Okogen’s ranpirnase platform, which, if successful, could lead to broad-spectrum antiviral treatments for other conditions, including systemic infections and dermatological diseases. The start of the EMERALD Trial brings the medical community one step closer to a versatile antiviral solution.
Summary
Okogen, Inc., a clinical-stage biotechnology company, has achieved a significant milestone by dosing the first patient in its Phase 1/2 EMERALD Trial for Treyegen™ (OKG-0303), an investigational treatment for acute infectious conjunctivitis. The first dosing took place at Ambade Eye Hospital in Nagpur, India, marking the beginning of a multicenter study that will evaluate the safety, tolerability, clinical outcomes, and antiviral and antibacterial activity of the therapy. Treyegen™ is designed as a single ophthalmic treatment that combines antiviral, antibacterial, and symptom-relieving mechanisms, addressing a critical need in conjunctivitis where the underlying cause is often unknown at diagnosis. For full details, including downloadable images and bios, click here.
Okogen’s broader strategy centers on its ranpirnase platform, a host-directed antiviral approach being advanced across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. Ophthalmology serves as the lead clinical proving ground, with the goal of leveraging insights from this area to expand into other antiviral therapies. The EMERALD Trial not only supports the development of Treyegen™ but also reinforces the potential of the ranpirnase platform across multiple therapeutic areas. For more information, visit www.okogen.com.
Source Statement
This curated news summary relied on content distributed by Reportable. Read the original source here, Okogen Doses First Patient in EMERALD Trial for Conjunctivitis Treatment
